WallStreetZenWallStreetZen

NYSEMKT: NBY
Novabay Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their NBY stock forecasts and price targets.

Forecast return on equity

Is NBY forecast to generate an efficient return?

Company
-4,360.95%
Industry
12.49%
Market
330.34%
NBY's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NBY forecast to generate an efficient return on assets?

Company
-1,386.95%
Industry
12.93%
NBY is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NBY earnings per share forecast

What is NBY's earnings per share in the next 2 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$0.87-137.28%
Avg 2 year Forecast
-$0.38-116.47%

NBY revenue forecast

What is NBY's revenue in the next 2 years based on estimates from 2 analysts?

Avg 1 year Forecast
$12.1M+328.27%
Avg 2 year Forecast
$16.0M+465.51%
NBY's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

NBY revenue growth forecast

How is NBY forecast to perform vs Biotechnology companies and vs the US market?

Company
328.27%
Industry
9,351.03%
Market
1,449.04%
NBY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NBY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NBY vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NBY$2.71N/AN/A
TECX$18.39$72.00+291.52%Strong Buy
CTNM$11.58$19.25+66.23%Strong Buy
CLLS$4.79$8.00+67.01%Strong Buy
LRMR$3.92$16.60+323.47%Buy
View Top Biotech Stocks

Novabay Pharmaceuticals Stock Forecast FAQ

What is NBY's earnings growth forecast for 2025-2026?

(NYSEMKT: NBY) Novabay Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 206.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 2,999.5%.

Novabay Pharmaceuticals's earnings in 2025 is $3,243,000.On average, 2 Wall Street analysts forecast NBY's earnings for 2025 to be -$109,452,937, with the lowest NBY earnings forecast at -$106,201,859, and the highest NBY earnings forecast at -$113,787,706.

In 2026, NBY is forecast to generate -$48,362,925 in earnings, with the lowest earnings forecast at -$46,926,403 and the highest earnings forecast at -$50,278,289.

If you're new to stock investing, here's how to buy Novabay Pharmaceuticals stock.

What is NBY's revenue growth forecast for 2025-2026?

(NYSEMKT: NBY) Novabay Pharmaceuticals's forecast annual revenue growth rate of 328.27% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 9,351.03%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,449.04%.

Novabay Pharmaceuticals's revenue in 2025 is $2,830,000.On average, 2 Wall Street analysts forecast NBY's revenue for 2025 to be $1,527,250,278, with the lowest NBY revenue forecast at $1,481,886,408, and the highest NBY revenue forecast at $1,587,735,437.

In 2026, NBY is forecast to generate $2,016,676,027 in revenue, with the lowest revenue forecast at $1,956,820,921 and the highest revenue forecast at $2,096,566,842.

What is NBY's forecast return on assets (ROA) for 2025-2026?

(NYSEMKT: NBY) forecast ROA is -1,386.95%, which is lower than the forecast US Biotechnology industry average of 12.93%.

What is NBY's Earnings Per Share (EPS) forecast for 2025-2026?

(NYSEMKT: NBY) Novabay Pharmaceuticals's current Earnings Per Share (EPS) is $2.33. On average, analysts forecast that NBY's EPS will be -$0.87 for 2025, with the lowest EPS forecast at -$0.84, and the highest EPS forecast at -$0.90. In 2026, NBY's EPS is forecast to hit -$0.38 (min: -$0.37, max: -$0.40).

What is NBY's forecast return on equity (ROE) for 2025-2026?

(NYSEMKT: NBY) forecast ROE is -4,360.95%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.